Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20275114 | 1.00 | NOTUM (0.33) | NOTUMPOLBKCNK3 | |
| SCHEMBL20553900 | 0.83 | — | — | |
| SCHEMBL19765485 | 0.82 | SMN1; SMN2 (0.37) | NOTUMPOLB | |
| SCHEMBL16300580 | 0.78 | ATM (0.32) | POLB | |
| SCHEMBL16800202 | 0.76 | CHRM2 (0.37) | — | |
| SCHEMBL20149071 | 0.73 | KCNK3 (0.33) | NOTUMPOLBKCNK3 | |
| SCHEMBL19389230 | 0.73 | RIPK1 (0.41) | — | |
| SCHEMBL16691883 | 0.72 | NOTUM (0.32) | NOTUMPOLBKCNK3 | |
| SCHEMBL21238986 | 0.71 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL14886274 | 0.70 | CYP3A4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556951-B2 | Anti-CD33 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2020-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556951-B2 | Anti-CD33 antibodies and immunoconjugates | CD63, NEU3, ENTPD3 | NOTUM 3115/4885POLB 4857/4885KCNK3 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.